Pure Global
NCT06235229

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
Gracell Biotechnologies Ltd.·Phase 1/2·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
GC012F
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Gracell Biotechnologies Ltd.
Location
Shanghai,Hangzhou, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Dec 07, 2023
End date
Jun 01, 2026
Enrollment
110 participants
Primary outcome

Phase 1: Dose-limiting toxicities,Phase 2: Overall response rate

Summary

This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety
 of GC012F in subjects with relapsed/refractory multiple myeloma.

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06235229
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06235229 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Gracell Biotechnologies Ltd. and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 110 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.